Table of Content

1. Research Framework
1.1. Research Objective
1.2. Product Type Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Sources
2.2. Quantitative Research
2.2.1. Primary and Secondary Sources
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Key Questionnaire asked during Primary Interviews
2.6. Key Primary Responses
2.7. Market Size Estimation
2.8. Assumption for the Study
2.9. Market Breakdown & Data Triangulation

3. Executive Summary

4. India Generic Drugs Market – Industry Insights
4.1. Value Chain
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.2.4. Challenges
4.3. Recent Developments / Technical Landscape
4.4. Regulatory Framework
4.5. Porter’s Five Forces Analysis
4.6. PESTEL Analysis

5. India Generic Drugs Market Overview, 2018-2028
5.1. Market Size & Forecast
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product Type
5.2.1.1. Simple Generics
5.2.1.2. Super Generics
5.2.1.3. Biosimilars
5.2.2. By Route of Administration
5.2.2.1. Oral
5.2.2.2. Topical
5.2.2.3. Injectable
5.2.2.4. Others
5.2.3. By Application
5.2.3.1. Cardiovascular Products
5.2.3.2. Anti-infective Drugs
5.2.3.3. Anti-arthritis Drugs
5.2.3.4. Central Nervous System Drugs
5.2.3.5. Anti-Cancer Drugs
5.2.3.6. Respiratory Products
5.2.3.7. Others
5.2.4. By Distribution Channel
5.2.4.1. Hospitals/Clinics
5.2.4.2. Retail Pharmacies
5.2.4.3. Other

6. Competitive Landscape
6.1.1. List of Key Producers and Their Offerings
6.1.2. Market Share / Ranking Analysis (2021)
6.1.3. Competitive Benchmarking, By Operating Parameters

7. COVID-19 Impact

8. Company Profiles (Company Overview, Financial Matrix, Key Product Type landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
8.1. Teva Pharmaceutical Industries
8.2. Wockhardt Pharmaceutical
8.3. Sandoz, A Novartis division
8.4. Fresenius Kabi
8.5. Aurobindo Pharma
8.6. Sun Pharma
8.7. Dr. Reddy
8.8. Lupin
8.9. Cipla
8.10. Viatris
8.11. Other Prominent Players

9. Key Strategic Recommendations

* Financial information of non-listed Companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth study during the final deliverable.

List of Figures

Fig 1: India Generic Drugs Segmentation
Fig 2: India Generic Drugs Market Value Chain Analysis
Fig 3: India Generic Drugs Market Size, By Value (USD Million), 2018-2028
Fig 4: India Generic Drugs Market Share, By Product Type, By Value, 2018-2028
Fig 5: India Generic Drugs Market Share, By Route of Administration, By Value, 2018-2028
Fig 6: India Generic Drugs Market Share, By Application, By Value, 2018-2028
Fig 7: India Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028
Fig 8: Company Share Analysis, 2021

List of Tables

Table 1: India Generic Drugs Size, By Product Type, By Value, 2018-2028
Table 2: India Generic Drugs Market Size, By Route of Administration, By Value, 2018-2028
Table 3: India Generic Drugs Market Size, By Application, By Value, 2018-2028
Table 4: India Generic Drugs Market Size, By Distribution Channel, By Value, 2018-2028
Table 5: Teva Pharmaceutical Industries Business Overview
Table 6: Teva Pharmaceutical Industries Financial Analysis
Table 7: Wockhardt Pharmaceutical Business Overview
Table 8: Wockhardt Pharmaceutical Financial Analysis
Table 9: Sandoz, A Novartis division Business Overview
Table 10: Sandoz, A Novartis division Financial Overview
Table 11: Fresenius Kabi Business Overview
Table 12: Fresenius Kabi Financial Overview
Table 13: Aurobindo Pharma Business Overview
Table 14: Aurobindo Pharma Financial Overview
Table 15: Sun Pharma Business Overview
Table 16: Sun Pharma Financial Analysis
Table 17: Dr. Reddy Business Overview
Table 18: Dr. Reddy Financial Analysis
Table 19: Lupin Business Overview
Table 20: Lupin Financial Overview
Table 21: Cipla Business Overview
Table 22: Cipla Financial Overview
Table 23: Viatris Business Overview
Table 24: Viatris Financial Overview